Clinical Trials Directory

Trials / Terminated

TerminatedNCT00078806

Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis

A Phase 3 Safety and Efficacy Study of Etanercept In Children With Systemic Onset Juvenile Rheumatoid Arthritis

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
19 (actual)
Sponsor
Amgen · Industry
Sex
All
Age
2 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study was to determine the efficacy of etanercept in pediatric patients with systemically active system onset juvenile rheumatoid arthritis (SOJRA).

Detailed description

Participants were to receive etanercept at a dose of 0.4 mg/kg twice weekly in Part 1A. Participants who had a partial response (not able to reduce prednisone dose by 50% of the baseline dose in 5 months) while on 0.4 mg/kg twice weekly etanercept in Part 1A were to enter Part 1B for up to 4 months and were to have the dose of etanercept increased to 0.8 mg/kg twice weekly. Participants who did not meet the response criteria in Part 1A or Part 1B of the study were to be withdrawn from the study as non-responders. Participants who responded in either Part 1A or Part 1B were randomized into Part 2, where they received etanercept or matching placebo in a double-blind manner twice weekly for up to 3 months. In Part 2, participants were stratified by the dosage of etanercept (0.4 mg/kg or 0.8 mg/kg) they were receiving in Part 1A or Part 1B. Participants could enter Part 3, the open-label re-treatment portion of the study, only if they had been entered into Part 2 of the study and had either flared in Part 2 or had completed 3 months of treatment in Part 2. The maximum time participants could receive etanercept in Part 2 and Part 3 combined was 12 months.

Conditions

Interventions

TypeNameDescription
DRUGEtanerceptAdministered by subcutaneous injection twice a week
DRUGPlaceboAdministered by subcutaneous injection twice a week

Timeline

Start date
2001-06-04
Primary completion
2004-05-06
Completion
2004-05-06
First posted
2004-03-09
Last updated
2019-09-25
Results posted
2019-09-25

Source: ClinicalTrials.gov record NCT00078806. Inclusion in this directory is not an endorsement.

Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis (NCT00078806) · Clinical Trials Directory